HRP960014A2 - New applications of lysozyme dimer - Google Patents

New applications of lysozyme dimer Download PDF

Info

Publication number: HRP960014A2
Authority: HR; Croatia
Prior art keywords: lysozyme; lysozyme dimer; preparation; klp; dimer
Prior art date: 1995-01-13

Application number

HR95110638.4A

Other languages

English (en)

Croatian (hr)

Inventor

Witold Kiczka

Original Assignee

Witold Kiczka

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-13

Filing date

1996-01-12

Publication date

1997-12-31

1996-01-12 Application filed by Witold Kiczka filed Critical Witold Kiczka

1997-12-31 Publication of HRP960014A2 publication Critical patent/HRP960014A2/hr

Links

102000016943 Muramidase Human genes 0.000 title claims description 92
108010014251 Muramidase Proteins 0.000 title claims description 92
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title claims description 92
229960000274 lysozyme Drugs 0.000 title claims description 92
235000010335 lysozyme Nutrition 0.000 title claims description 92
239000004325 lysozyme Substances 0.000 title claims description 92
239000000539 dimer Substances 0.000 title claims description 78
238000011282 treatment Methods 0.000 claims description 46
238000002360 preparation method Methods 0.000 claims description 40
235000019688 fish Nutrition 0.000 claims description 31
241000251468 Actinopterygii Species 0.000 claims description 29
230000003779 hair growth Effects 0.000 claims description 28
241001465754 Metazoa Species 0.000 claims description 24
238000000034 method Methods 0.000 claims description 22
208000004631 alopecia areata Diseases 0.000 claims description 16
241000700605 Viruses Species 0.000 claims description 15
239000000178 monomer Substances 0.000 claims description 14
206010028980 Neoplasm Diseases 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 11
239000000825 pharmaceutical preparation Substances 0.000 claims description 11
201000010099 disease Diseases 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
208000015181 infectious disease Diseases 0.000 claims description 9
239000000047 product Substances 0.000 claims description 9
230000001225 therapeutic effect Effects 0.000 claims description 9
230000037396 body weight Effects 0.000 claims description 8
230000003449 preventive effect Effects 0.000 claims description 8
230000000638 stimulation Effects 0.000 claims description 8
241000282412 Homo Species 0.000 claims description 7
241000710921 Infectious pancreatic necrosis virus Species 0.000 claims description 7
201000011510 cancer Diseases 0.000 claims description 7
210000000987 immune system Anatomy 0.000 claims description 7
230000007246 mechanism Effects 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 7
230000009471 action Effects 0.000 claims description 6
239000006227 byproduct Substances 0.000 claims description 6
208000010824 fish disease Diseases 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
208000032839 leukemia Diseases 0.000 claims description 5
239000007787 solid Substances 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 4
208000037824 growth disorder Diseases 0.000 claims description 4
244000005700 microbiome Species 0.000 claims description 4
239000003755 preservative agent Substances 0.000 claims description 4
230000002335 preservative effect Effects 0.000 claims description 4
230000004936 stimulating effect Effects 0.000 claims description 4
206010017553 Furuncle Diseases 0.000 claims description 3
208000003512 furunculosis Diseases 0.000 claims description 3
239000008187 granular material Substances 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
239000002904 solvent Substances 0.000 claims description 3
239000013589 supplement Substances 0.000 claims description 3
238000003786 synthesis reaction Methods 0.000 claims description 3
241000972773 Aulopiformes Species 0.000 claims description 2
241000700721 Hepatitis B virus Species 0.000 claims description 2
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 2
241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 2
241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 2
230000002421 anti-septic effect Effects 0.000 claims description 2
239000002775 capsule Substances 0.000 claims description 2
239000008298 dragée Substances 0.000 claims description 2
235000013601 eggs Nutrition 0.000 claims description 2
239000000499 gel Substances 0.000 claims description 2
238000010353 genetic engineering Methods 0.000 claims description 2
239000002674 ointment Substances 0.000 claims description 2
238000007911 parenteral administration Methods 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
230000001172 regenerating effect Effects 0.000 claims description 2
235000019515 salmon Nutrition 0.000 claims description 2
239000003826 tablet Substances 0.000 claims description 2
241001430294 unidentified retrovirus Species 0.000 claims description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
241001327682 Oncorhynchus mykiss irideus Species 0.000 claims 1
238000006471 dimerization reaction Methods 0.000 claims 1
230000000694 effects Effects 0.000 description 26
210000004027 cell Anatomy 0.000 description 18
238000002474 experimental method Methods 0.000 description 17
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 16
238000012360 testing method Methods 0.000 description 15
239000003814 drug Substances 0.000 description 13
229940079593 drug Drugs 0.000 description 11
210000004209 hair Anatomy 0.000 description 11
210000004761 scalp Anatomy 0.000 description 11
241000699670 Mus sp. Species 0.000 description 10
230000000242 pagocytic effect Effects 0.000 description 10
210000001541 thymus gland Anatomy 0.000 description 10
238000001727 in vivo Methods 0.000 description 9
150000003254 radicals Chemical class 0.000 description 9
210000000952 spleen Anatomy 0.000 description 9
241000257303 Hymenoptera Species 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
230000008260 defense mechanism Effects 0.000 description 8
210000001165 lymph node Anatomy 0.000 description 8
238000011640 AKR mouse Methods 0.000 description 7
239000006210 lotion Substances 0.000 description 7
238000011160 research Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
201000004384 Alopecia Diseases 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
230000000052 comparative effect Effects 0.000 description 6
235000013305 food Nutrition 0.000 description 6
230000003659 hair regrowth Effects 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
229960003632 minoxidil Drugs 0.000 description 6
230000008569 process Effects 0.000 description 6
208000035143 Bacterial infection Diseases 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
208000022362 bacterial infectious disease Diseases 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
230000006872 improvement Effects 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
102000003896 Myeloperoxidases Human genes 0.000 description 4
108090000235 Myeloperoxidases Proteins 0.000 description 4
241000277275 Oncorhynchus mykiss Species 0.000 description 4
231100000360 alopecia Toxicity 0.000 description 4
238000011161 development Methods 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
230000003308 immunostimulating effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
238000009372 pisciculture Methods 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
108010075016 Ceruloplasmin Proteins 0.000 description 3
102100023321 Ceruloplasmin Human genes 0.000 description 3
208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
244000062730 Melissa officinalis Species 0.000 description 3
235000010654 Melissa officinalis Nutrition 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
230000002411 adverse Effects 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
238000009341 apiculture Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000007124 immune defense Effects 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000000865 liniment Substances 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
208000003747 lymphoid leukemia Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
210000001835 viscera Anatomy 0.000 description 3
241000607525 Aeromonas salmonicida Species 0.000 description 2
229920002498 Beta-glucan Polymers 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
241000701931 Canine parvovirus Species 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
208000003251 Pruritus Diseases 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000835 fiber Substances 0.000 description 2
108010074605 gamma-Globulins Proteins 0.000 description 2
210000002816 gill Anatomy 0.000 description 2
208000024963 hair loss Diseases 0.000 description 2
230000003676 hair loss Effects 0.000 description 2
230000035876 healing Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
235000012907 honey Nutrition 0.000 description 2
230000028993 immune response Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
230000007803 itching Effects 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
230000001926 lymphatic effect Effects 0.000 description 2
230000002132 lysosomal effect Effects 0.000 description 2
230000004660 morphological change Effects 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
210000001539 phagocyte Anatomy 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
210000003660 reticulum Anatomy 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
230000003797 telogen phase Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
206010001766 Alopecia totalis Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
102000003846 Carbonic anhydrases Human genes 0.000 description 1
108090000209 Carbonic anhydrases Proteins 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
206010013082 Discomfort Diseases 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241001430197 Mollicutes Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
241000277334 Oncorhynchus Species 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
108010065081 Phosphorylase b Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000277331 Salmonidae Species 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
208000030695 Sparse hair Diseases 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
102000002070 Transferrins Human genes 0.000 description 1
108010015865 Transferrins Proteins 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
108070000030 Viral receptors Proteins 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
206010048038 Wound infection Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
201000006966 adult T-cell leukemia Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
238000002266 amputation Methods 0.000 description 1
238000003975 animal breeding Methods 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001420 bacteriolytic effect Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000009702 cancer cell proliferation Effects 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000008859 change Effects 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000011254 conventional chemotherapy Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001461 cytolytic effect Effects 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000000447 dimerizing effect Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000009313 farming Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003324 growth hormone secretagogue Substances 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000002895 hyperchromatic effect Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
244000045947 parasite Species 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000035515 penetration Effects 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
210000004176 reticulum cell Anatomy 0.000 description 1
239000011669 selenium Substances 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
235000011649 selenium Nutrition 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
239000013638 trimer Substances 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000005353 urine analysis Methods 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Toxicology (AREA)
Reproductive Health (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Fish Paste Products (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HR95110638.4A 1995-01-13 1996-01-12 New applications of lysozyme dimer HRP960014A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP95100446		1995-01-13
EP95110638		1995-07-07

Publications (1)

Publication Number	Publication Date
HRP960014A2 true HRP960014A2 (en)	1997-12-31

Family

ID=26138401

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR95110638.4A HRP960014A2 (en)	1995-01-13	1996-01-12	New applications of lysozyme dimer

Country Status (37)

Country	Link
EP (2)	EP1086703A3 (fr)
JP (1)	JPH10511974A (fr)
KR (1)	KR100420377B1 (fr)
CN (1)	CN1090506C (fr)
AP (2)	AP628A (fr)
AT (1)	ATE218367T1 (fr)
AU (1)	AU709620B2 (fr)
BA (1)	BA96074A (fr)
BG (1)	BG62239B1 (fr)
BR (1)	BR9606973A (fr)
CA (1)	CA2210091A1 (fr)
CZ (1)	CZ293353B6 (fr)
DE (2)	DE69621589D1 (fr)
DZ (1)	DZ1964A1 (fr)
EA (1)	EA001462B1 (fr)
EE (1)	EE9700154A (fr)
ES (1)	ES2109208T1 (fr)
FI (1)	FI972943L (fr)
GB (1)	GB2311724B (fr)
GE (1)	GEP20012571B (fr)
GR (1)	GR970300047T1 (fr)
HR (1)	HRP960014A2 (fr)
HU (1)	HU223903B1 (fr)
IL (1)	IL116737A (fr)
MA (1)	MA23775A1 (fr)
MD (1)	MD1633C2 (fr)
MY (1)	MY132437A (fr)
NO (1)	NO973203D0 (fr)
NZ (1)	NZ298432A (fr)
OA (1)	OA10436A (fr)
PL (1)	PL185678B1 (fr)
SK (1)	SK94297A3 (fr)
SV (1)	SV1996000001A (fr)
TN (1)	TNSN96004A1 (fr)
TR (1)	TR199700633T1 (fr)
UA (1)	UA50728C2 (fr)
WO (1)	WO1996021463A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6123937A (en) *	1997-03-14	2000-09-26	Nika Health Products, Limited	Applications of lysozyme dimer
ATE211389T1 (de) *	1998-04-27	2002-01-15	Nika Health Products Ltd	Zusammensetzung zur verbesserung der fruchtbarkeit und ihre verwendung
AUPP489798A0 (en) *	1998-07-28	1998-08-20	Mediko Pty Ltd	Hair growth/maintenance compositions and methods
EP2134354A4 (fr) *	2007-03-02	2012-03-21	Saint Simeon Lda	Composition et procédé de traitement du virus de papillome et des sarcoïdes équins
CN103518978B (zh) *	2013-10-22	2016-01-13	上海艾魁英生物科技有限公司	新型溶菌酶制剂及其制备方法
CN105828829A (zh) *	2013-12-18	2016-08-03	帝斯曼知识产权资产管理有限公司	用于含角蛋白的组织的包含溶菌酶水解物的组合物
CN104585546B (zh) *	2015-01-20	2019-02-05	上海海洋大学	一种促生长抗应激罗非鱼饲料及其制备方法
CN105707509B (zh) *	2016-01-25	2018-12-28	浙江艾杰斯生物科技有限公司	一种用于防治草鱼烂腮病的饲料添加剂
WO2020099556A1 (fr)	2018-11-14	2020-05-22	Universiteit Antwerpen	Lysozyme oxydé
EP4003300A4 (fr) *	2019-07-26	2023-06-28	Infinant Health, Inc	Compositions nutritives contenant des protéines bioactives
CN111657407A (zh) *	2020-05-14	2020-09-15	上海艾魁英生物科技有限公司	提高断奶仔猪非特异性免疫功能的饲料添加剂、其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5533408A (en) *	1978-08-30	1980-03-08	Eisai Co Ltd	Immunity-increasing agent
JPS5543040A (en) *	1978-09-25	1980-03-26	Eisai Co Ltd	Immunity raising agent
DE3230999A1 (de) *	1982-08-20	1984-02-23	Philips Kommunikations Industrie AG, 8500 Nürnberg	Verfahren zur zugriffssteuerung bei einem nachrichtensystem
EP0181634A3 (fr) *	1984-11-14	1987-09-09	Takeda Chemical Industries, Ltd.	Gène synthétique pour lysozyme humaine
RU2061496C1 (ru) *	1985-08-02	1996-06-10	Институт общей патологии и экологии человека	Средство, стимулирующее эритропоэз
JPH01501939A (ja) *	1987-01-28	1989-07-06	オーソ・フアーマシユーチカル・コーポレーシヨン	免疫抑制ペプチドおよび使用法
US5200182A (en) *	1988-05-26	1993-04-06	Nika Health Products, Ltd.	Antiviral or antibacterial composition and method of use
AU645252B2 (en) *	1990-01-08	1994-01-13	Nika Health Products Ltd.	Method of producing ribonuclease dimers
CA2073351C (fr) *	1990-01-08	2001-10-16	Nika Health Products, Inc.	Dimeres de lysozymes et methode de preparation correspondante
PL173978B1 (pl) *	1992-07-13	1998-05-29	Nika Health Products Ltd	Sposób oddziaływania na wydzielanie cytokin w hodowli limfocytów krwi obwodowej
RU2082413C1 (ru) *	1993-06-30	1997-06-27	Нижегородский государственный медицинский институт	Способ лечения язвенной болезни двенадцатиперстной кишки
RU2071339C1 (ru) *	1994-07-25	1997-01-10	Щербакова Элеонора Григорьевна	Средство для лечения и профилактики дисбактериоза
RU2123345C1 (ru) *	1997-07-31	1998-12-20	Научно-исследовательский институт детского питания Российской Академии сельскохозяйственных наук	Средство для лечения дисбактериоза

1996
- 1996-01-10 DZ DZ960005A patent/DZ1964A1/fr active
- 1996-01-11 TN TNTNSN96004A patent/TNSN96004A1/fr unknown
- 1996-01-11 IL IL11673796A patent/IL116737A/xx not_active IP Right Cessation
- 1996-01-12 MY MYPI96000118A patent/MY132437A/en unknown
- 1996-01-12 SV SV1996000001A patent/SV1996000001A/es unknown
- 1996-01-12 BA BA960074A patent/BA96074A/bs unknown
- 1996-01-12 AP APAP/P/1996/000783A patent/AP628A/en active
- 1996-01-12 HR HR95110638.4A patent/HRP960014A2/hr not_active Application Discontinuation
- 1996-01-13 TR TR97/00633T patent/TR199700633T1/xx unknown
- 1996-01-13 AU AU43916/96A patent/AU709620B2/en not_active Ceased
- 1996-01-13 HU HU9801689A patent/HU223903B1/hu not_active IP Right Cessation
- 1996-01-13 AT AT96900321T patent/ATE218367T1/de not_active IP Right Cessation
- 1996-01-13 BR BR9606973A patent/BR9606973A/pt not_active Application Discontinuation
- 1996-01-13 NZ NZ298432A patent/NZ298432A/en unknown
- 1996-01-13 FI FI972943A patent/FI972943L/fi unknown
- 1996-01-13 PL PL96321546A patent/PL185678B1/pl not_active IP Right Cessation
- 1996-01-13 KR KR1019970704726A patent/KR100420377B1/ko not_active Expired - Fee Related
- 1996-01-13 CA CA002210091A patent/CA2210091A1/fr not_active Abandoned
- 1996-01-13 JP JP8521448A patent/JPH10511974A/ja active Pending
- 1996-01-13 DE DE69621589T patent/DE69621589D1/de not_active Expired - Lifetime
- 1996-01-13 WO PCT/EP1996/000135 patent/WO1996021463A2/fr not_active Ceased
- 1996-01-13 GE GEAP19963815A patent/GEP20012571B/en unknown
- 1996-01-13 CZ CZ19972202A patent/CZ293353B6/cs not_active IP Right Cessation
- 1996-01-13 EP EP00124590A patent/EP1086703A3/fr not_active Withdrawn
- 1996-01-13 AP APAP/P/1997/001024A patent/AP871A/en active
- 1996-01-13 EP EP96900321A patent/EP0804227B1/fr not_active Expired - Lifetime
- 1996-01-13 EA EA199700101A patent/EA001462B1/ru not_active IP Right Cessation
- 1996-01-13 EE EE9700154A patent/EE9700154A/xx unknown
- 1996-01-13 GB GB9714354A patent/GB2311724B/en not_active Expired - Fee Related
- 1996-01-13 UA UA97063430A patent/UA50728C2/uk unknown
- 1996-01-13 ES ES96900321T patent/ES2109208T1/es active Pending
- 1996-01-13 CN CN96192331A patent/CN1090506C/zh not_active Expired - Fee Related
- 1996-01-13 MD MD97-0244A patent/MD1633C2/ro unknown
- 1996-01-13 SK SK942-97A patent/SK94297A3/sk unknown
- 1996-01-13 DE DE0804227T patent/DE804227T1/de active Pending
- 1996-01-15 MA MA24130A patent/MA23775A1/fr unknown
1997
- 1997-06-30 BG BG101709A patent/BG62239B1/bg unknown
- 1997-07-10 NO NO973203A patent/NO973203D0/no not_active Application Discontinuation
- 1997-07-11 OA OA70048A patent/OA10436A/en unknown
- 1997-12-31 GR GR970300047T patent/GR970300047T1/el unknown

Also Published As

Publication number	Publication date
MA23775A1 (fr)	1996-10-01
EE9700154A (et)	1997-12-15
DZ1964A1 (fr)	2002-10-15
CA2210091A1 (fr)	1996-07-18
HUP9801689A2 (hu)	1998-10-28
HUP9801689A3 (en)	2000-07-28
UA50728C2 (uk)	2002-11-15
ATE218367T1 (de)	2002-06-15
EA199700101A1 (ru)	1997-12-30
CN1090506C (zh)	2002-09-11
NO973203L (no)	1997-07-10
EP1086703A2 (fr)	2001-03-28
IL116737A (en)	2000-02-17
EP0804227A2 (fr)	1997-11-05
WO1996021463A3 (fr)	1996-09-19
EA001462B1 (ru)	2001-04-23
FI972943A7 (fi)	1997-07-11
MD1633B2 (en)	2001-03-31
AP871A (en)	2000-09-10
CZ220297A3 (cs)	1998-02-18
HU223903B1 (hu)	2005-03-29
GB9714354D0 (en)	1997-09-10
OA10436A (en)	2001-12-07
GB2311724B (en)	1999-07-21
NO973203D0 (no)	1997-07-10
MD1633C2 (ro)	2001-10-31
GB2311724A (en)	1997-10-08
MY132437A (en)	2007-10-31
BG62239B1 (bg)	1999-06-30
NZ298432A (en)	2001-03-30
GEP20012571B (en)	2001-11-26
JPH10511974A (ja)	1998-11-17
AP628A (en)	1998-02-27
PL321546A1 (en)	1997-12-08
SK94297A3 (en)	1998-01-14
BR9606973A (pt)	1999-01-26
EP0804227B1 (fr)	2002-06-05
DE69621589D1 (de)	2002-07-11
FI972943A0 (fi)	1997-07-11
GR970300047T1 (en)	1997-12-31
CZ293353B6 (cs)	2004-04-14
MD970244A (en)	1999-05-31
AP9600783A0 (en)	1996-04-30
CN1177303A (zh)	1998-03-25
PL185678B1 (pl)	2003-07-31
DE804227T1 (de)	1998-04-09
KR100420377B1 (ko)	2004-05-20
FI972943L (fi)	1997-07-11
TR199700633T1 (xx)	1998-01-21
SV1996000001A (es)	1997-02-17
KR19980701337A (ko)	1998-05-15
BA96074A (bs)	1999-08-02
AU4391696A (en)	1996-07-31
WO1996021463A2 (fr)	1996-07-18
ES2109208T1 (es)	1998-01-16
AU709620B2 (en)	1999-09-02
BG101709A (en)	1998-03-31
IL116737A0 (en)	1996-05-14
EP1086703A3 (fr)	2001-05-02
HK1002060A1 (en)	1998-07-31
TNSN96004A1 (fr)	2005-03-15
AP9701024A0 (en)	1997-07-31

Legal Events

Date	Code	Title	Description
1997-12-31	A1OB	Publication of a patent application
1998-03-13	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2002-01-12	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20020112 Year of fee payment: 7
2003-04-15	ODBI	Application refused

Publication	Publication Date	Title
Kohchi et al.	2006	Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory
RS49831B (sr)	2008-08-07	Farmaceutske kompozicije tizoksanida i nitazoksanida
AU709620B2 (en)	1999-09-02	New applications of lysozyme dimer
US6183742B1 (en)	2001-02-06	Applications of lysozyme dimer
RU2647455C1 (ru)	2018-03-15	Композиция, обладающая иммуностимулирующим действием для сублингвального применения
WO2002074311A1 (fr)	2002-09-26	Preparation medicinale antitumorale, antivirale, antibacterienne, antiparasitaire, anti-inflammatoire, antifongique et immunomodulatrice, procede de fabrication et formes de medicaments
JPH07508010A (ja)	1995-09-07	ＤＮＡウイルス感染の治療のための薬物の製造のための膜翅類昆虫（ｈｙｍｅｎｏｐｔｅｒａ）毒の使用
RU2105504C1 (ru)	1998-02-27	Пищевая биологически активная добавка "тинростим-с"
CN115515600B (zh)	2024-06-25	免疫功能兴奋用组合物
US9308243B2 (en)	2016-04-12	Cellular enhancements in biological systems through the use of li-pofullerene and peptide group combinations
RU2378011C1 (ru)	2010-01-10	Способ профилактики бруцеллеза крупного рогатого скота
KR20060038387A (ko)	2006-05-03	화학요법을 받고 있는 암 환자를 치료하는 방법
US20020098171A1 (en)	2002-07-25	New application of lysozyme dimer
RU2136303C1 (ru)	1999-09-10	Способ получения средства для лечения ларвального и стробилярного эхинококкозов "чеблин ск-1"
MXPA97005246A (en)	1998-07-03	New applications of dimero de lisoz
RU2414223C1 (ru)	2011-03-20	Средство, обладающее иммуностимулирующим и гемостимулирующим действием
RU2553308C1 (ru)	2015-06-10	Капли плетнева, обладающие противовирусным и иммуномодулирующим эффектами
Aswad et al.	2025	Formulation and Evaluation of Snakehead Fish Mucus Emulgel for Enhanced Wound Healing and Antibacterial Activity
RU2329791C2 (ru)	2008-07-27	Способ стимуляции гемопоэза при лечении острой лучевой болезни у собак
WO2005042015A1 (fr)	2005-05-12	Composition pharmaceutique anti-herpetique, procede de production d'une forme medicamenteuse a partir de cette composition et procede d'utilisation correspondant
Broshkov et al.	2022	METHODS FOR REGULATION OF IMMUNE REACTIVITY IN DOGS: a monograph
RU2568869C1 (ru)	2015-11-20	Способ лечения демодекоза собак
SU1651905A1 (ru)	1991-05-30	Способ лечени дикроцелиоза овец
WO2009042708A1 (fr)	2009-04-02	Composition anti-inflammatoire régénérante et procédé de traitement d'une dystrophie rétinienne avec cette dernière
ITRG980001U1 (it)	1999-07-19	Metodo sull'uso dell'nac1 per la preparazione di farmaci e alimenti per la cura e la profilassi della leishmaniosi.